CClinicalTrials.gg
Status unknownNCT02132104Updated Oct 21, 2014

Efficiency of Amnion Graft to Prevent Intrauterine Adhesions After Hysteroscopic Surgery

An interventional study of Uterine application of amnion membrane and Foley balloon in Intrauterine Adhesions, sponsored by Capital Medical University. Status unknown at 2 sites in China. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-21.

Sponsored by Capital Medical University · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Oct 2014), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The purpose of the study is to evaluate whether human amnion graft reduces the reformation of severe intrauterine adhesions (IUA) following hysteroscopic adhesiolysis.

Read the detailed description

Background

IUA is a consequence of trauma to the endometrium, producing partial or complete obliteration in the uterine cavity and/or the cervical canal, resulting in conditions such as menstrual abnormalities, infertility, and recurrent pregnancy loss. The outcome of hysteroscopic adhesiolysis for IUA is significantly affected by recurrence of intrauterine adhesions. The IUA research should be directed toward reduction of adhesion reformation with a view to improve outcome.

The reformation of intrauterine adhesions appears to be directly related to the severity of the adhesions. It has been reported that the recurrence rate for intrauterine adhesions ranges from 3.1% to 23.5% among all cases of intrauterine adhesions and from 20% to 62.5% in those with severe adhesions.

In this study, considering the high recurrent rate in severe IUA, investigator will focus on severe IUA cases.

Up to now several strategies are commonly employed by various investigators after division of intrauterine adhesions:

  1. Physical barriers have been used to promote regeneration of the endometrium and prevention of adhesions. The physical barriers include an intrauterine device (IUD), a Foley catheter, a number of modifications of hyaluronic acid and Auto-cross-linked hyaluronic acid gel.
  2. Hormonal treatment has been used to promote regeneration of the endometrium.
  3. Antibiotic therapy has been used to prevent infection which is a potent trigger for adhesion formation/reformation.
  4. Various medications have been described to increase vascular flow to endometrium, such as asprin, nitroglycerine and sildenafil citrate.

There is published data (Amer et al, 2010), which based on a plot prospective, randomised, comparative study that grafting of either fresh or dried amnion is a promising adjunctive procedure for decreasing recurrence of adhesions and encouraging endometrial regeneration after hysteroscopic lysis of severe intrauterine adhesions. However, the study had a small number of patients, the valid conclusion can not be drawn.

In this study, the aim is to compare the safety and the efficacy of insertion of intrauterine balloon + hormonal treatment with or without grafting amnion to prevent intrauterine adhesion formation/reformation following division of intrauterine adhesions.

Study Design

Patients with severe IUA are enrolled according to the classification of intrauterine adhesion by American Fertility Society.

208 patients with severe IUA were chosen at random and divided equally into those who received amnion graft, following hysteroscopic adhesiolysis (treatment groups) and to those who did not receive the amnion graft (control groups).

Intervention

Following hysteroscopic adhesiolysis, patients will be randomised to have a Foley balloon with or without amnion graft into the uterine cavity. Hormones therapy has been used after surgical treatment both in treatment groups and control groups. A second look and a third look hysteroscopy will be performed about 4 and 12 weeks after the initial operative hysteroscopy. The amount of adhesions, if any, during the initial and reexamine hysteroscopies will be scored.

Power calculation

The investigators' retrospective pilot study data showed that the recurrent rate of severe IUA is around 30% in amnion treatment groups, and around 47.5% in control groups. According to these data, investigators calculated the sample sizes of this study by using Cochran-Mantel-Haenszel test with software PASS 11. Investigators will recruit 104 patients in each group.

Group sample sizes of 104 in group one and 104 in group two achieve 85% power to detect a difference between the group proportions of -0.2000. The group two proportion is 0.5000. The group one proportion is assumed to be 0.5000 under the null hypothesis and 0.3000 under the alternative hypothesis. The test statistic used is the two-sided Z test (unpooled). The significance level of the test was targeted at 0.0500. The significance level actually achieved by this design is not available.

Statistics

Safety and efficacy were evaluated by software NCSS-PASS, using Two Independent Proportions (Non-Null Case) Power Analysis.

02

Conditions studied

  • Intrauterine Adhesions

Browse trials for

Keywords

  • Intrauterine adhesions
  • Asherman Syndrome
  • Amnion graft
03

In context

Tissue Adhesions

241 studies on the registry are indexed under Tissue Adhesions; 29 are open to participants now.

This study's planned enrollment of 208 is above the median of 60 across 184 interventional studies indexed under Tissue Adhesions.

Browse Tissue Adhesions studies →

Lead sponsor

Capital Medical University is the lead sponsor of 283 studies on the registry; 92 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • patients scheduled for adhesiolysis of intrauterine adhesions
  • patients willing to undergo followed hysteroscopy about 4 and 12 weeks after the surgery to assess the reformation of intrauterine adhesions.
  • Written, informed consent obtained.

Exclusion criteria

Exclusion Criteria:

  • ongoing pregnancy
  • Peroperative fever or infections
  • Malignancy
  • Precious pelvic inflammatory disease
  • Uterine fibroid (>3cm size)
  • endometriosis
  • Contraindications for anesthesia
  • Not able to read and/or understand informed consent.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
208 participants (estimated)

Study arms

  • Experimental
    amnion graft in severe IUA

    patients, who are with severe IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.

    Procedure: Uterine application of amnion membrane · Device: Foley balloon · Drug: Femoston

  • Sham comparator
    non-amnion graft in severe IUA

    patients, who are with severe IUA, treated by Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.

    Device: Foley balloon · Drug: Femoston

Interventions

  • ProcedureUterine application of amnion membrane

    Uterine application of amnion membrane following hysteroscopic adhesiolysis.

    Also known as: Human amnion membrane

  • DeviceFoley balloon

    Uterine application of Foley balloon

  • DrugFemoston

    Hormones treatment after surgery.

    Also known as: Hormones

06

What researchers measure

Primary outcomes

  1. safety of intrauterine application of amnion membrane

    patients treated by amnion membrane following their hysteroscopic procedure were followed for immediate and late adverse effect: fever, abnormal vaginal discharge, pelvic pain, increased intrauterine adhesion formation upon follow up and changes in menstrual pattern.

    Time frame: 3 months

Secondary outcomes

  1. efficacy of intrauterine application of amnion graft in reducing adhesion formation following hysteroscopic adhesiolysis.

    intrauterine adhesions were assessed and graded according to the American Fertility Society (AFS) score upon hysteroscopy follow up 4 and 12 weeks following initial treatment.

    Time frame: 3 months

07

Study locations

2 sites
  • Fu Xing Hospital, Capital Medical University
    Beijing, 100038, China
    • Shanshan Zheng · Contact · fxyykjk@sina.com · 0086 10 88062032
    • Qin Zhong · Contact · fxyykjk@sina.com · 0086 10 88062944
    • Xuebing Peng, MD · Principal investigator
    • TC Li, PhD · Sub investigator
    • Xiaoxia Peng, PhD · Sub investigator
  • Fu Xing Hospital, Capital Medical University
    Beijing, 100038, China
    • Shanshan Zheng · Contact · fxyykjk@sina.com · 0086 10 88062032
    • Qin Zhong · Contact · fxyykjk@sina.com · 008610 88062944
    • Xuebing Peng, MD · Principal investigator
08

References and documents

Publications

  • Yu D, Wong YM, Cheong Y, Xia E, Li TC. Asherman syndrome--one century later. Fertil Steril. 2008 Apr;89(4):759-79. doi: 10.1016/j.fertnstert.2008.02.096. PubMed 18406834 ↗
  • Amer MI, Abd-El-Maeboud KH, Abdelfatah I, Salama FA, Abdallah AS. Human amnion as a temporary biologic barrier after hysteroscopic lysis of severe intrauterine adhesions: pilot study. J Minim Invasive Gynecol. 2010 Sep-Oct;17(5):605-11. doi: 10.1016/j.jmig.2010.03.019. Epub 2010 Jun 23. PubMed 20576472 ↗
  • Amer MI, Abd-El-Maeboud KH. Amnion graft following hysteroscopic lysis of intrauterine adhesions. J Obstet Gynaecol Res. 2006 Dec;32(6):559-66. doi: 10.1111/j.1447-0756.2006.00454.x. PubMed 17100817 ↗
  • The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, mullerian anomalies and intrauterine adhesions. Fertil Steril. 1988 Jun;49(6):944-55. doi: 10.1016/s0015-0282(16)59942-7. No abstract available. PubMed 3371491 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02132104
Lead sponsor
Capital Medical University
Responsible party
XUEBING PENG (Associated Professor, Capital Medical University) — Principal investigator
First posted
May 7, 2014
Start date
Nov 2014
Primary completion
Aug 2016 (estimated)
Completion
Nov 2016 (estimated)
Last update
Oct 21, 2014

Study contacts

Xuebing Peng, MD
Contact
peng_xue_bing@hotmail.com
008613901297392
TC Li, PhD
study director · Hysteroscopic Center, Fu Xing Hospital
Xuebing Peng, MD
principal investigator · Hysteroscopic Center, Fu Xing Hospital
Enlan Xia, MD
study chair · Hysteroscopic Center, Fu Xing Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion